SCHEMBL24559245

SCHEMBL24559245

Cn1c(=O)c2c(ncn2Cc2ccc(C=C3C(=O)NC(=S)NC3=O)cc2)n(C)c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ ADORA2B P29275 7/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ RXFP1 Q9HBX9 2/20 0.58
▸ ABCC8 Q09428 1/20 0.58
▸ KCNJ11 Q14654 1/20 0.58
▸ HTT P42858 2/20 0.56
▸ UBE2N P61088 2/20 0.56
▸ GLA P06280 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ CASP1 P29466 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ PDE1A P54750 1/20 0.44
▸ PDE1B Q01064 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24559268 0.92 LMNA (0.63) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559303 0.91 LMNA (0.59) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559156 0.86 LMNA (0.49) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559158 0.84 LMNA (0.64) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559155 0.83 LMNA (0.57) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559151 0.83 LMNA (0.48) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559307 0.82 LMNA (0.61) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL17750785 0.81 LMNA (0.89) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559309 0.78 LMNA (0.58) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1
SCHEMBL24559153 0.77 LMNA (0.51) LMNAMAPK1ADORA2BSMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202821-A1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF PARG, PARP15, PLG LMNA 854/4885MAPK1 2790/4885ADORA2B 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback